A nanoencapsulated oral formulation of fenretinide promotes local and metastatic breast cancer dormancy in HER2/neu transgenic mice

A nanoencapsulated oral formulation of fenretinide promotes local and metastatic breast cancer dormancy in HER2/neu transgenic mice

Abstract Background Prevention and treatment of metastatic breast cancer (BC) is an unmet clinical need. The retinoic acid derivative fenretinide (FeR) was previously evaluated in Phase I-III clinical trials but, despite its excellent tolerability and antitumor activity in preclinical models, showed...

Full description

Saved in:
Bibliographic Details
Main Authors: Maria Laura De Angelis, Federica Francescangeli, Eleonora Aricò, Paola Verachi, Massimo Zucchetti, Cristina Matteo, Elena Petricci, Emanuela Pilozzi, Isabella Orienti, Alessandra Boe, Adriana Eramo, Rachele Rossi, Tiberio Corati, Daniele Macchia, Anna Maria Pacca, Ann Zeuner, Marta Baiocchi
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Fenretinide
Breast cancer
Tumor dormancy
Cancer stem cells
Retinoids
Metastasis
Online Access:https://doi.org/10.1186/s13046-024-03213-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13046-024-03213-6

Similar Items